Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3 Depression 3 Breast Neoplasms 2 Anxiety Disorders 2 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Lymphoma, Follicular 1 Lung Neoplasms 1 Hospice 1 Hematopoietic and Lymphoid System Neoplasm 1 Hematopoietic and Lymphatic System Neoplasm 1 Hematologic Neoplasms 1 Gynecologic Cancer 1 Gastrointestinal Neoplasms 1 Emotional Regulation 1 Colonic Neoplasms 1 Advanced Cancer 1 Acute Pain 1

Interventions

Nivolumab 20 Ipilimumab 10 Paclitaxel 7 linrodostat 6 Standard of Care 6 Sirolimus 5 Gemcitabine 5 Bevacizumab 5 temsirolimus 4 relatlimab 4 Pemetrexed 4 Docetaxel 4 Carboplatin 4 ARRY-334543 4 Vorinostat 3 Erlotinib Hydrochloride 3 Dasatinib 3 Cetuximab 3 regorafenib 2 olaparib 2 apatinib 2 anlotinib 2 abemaciclib 2 Trastuzumab 2 Surveys and Questionnaires 2 Sunitinib 2 Sorafenib 2 Olanzapine 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Cancer × Psychotherapy × Clear all

NCT05398484 2025-12-04

Psilocybin Therapy in Advanced Cancer

NYU Langone Health

Phase 2/3 Recruiting

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡